Bmx-Cre-ERT2 Mouse

Gene/Protein Targets

Estragen receptor (ERT2) under the Bone marrow x (Bmx) promoter.

Relevance: Cre-ERT under Bmx promoter enabling inducible conditional recombinase expression in arterial endothelial cells (tissue-specific loxP knockout/knockin/transgene). The Bmx-Cre-ERT2 mouse exhibits tissue-specific expression of an inducible Cre-ERT2 fusion protein, enabling tamoxifen-induced Cre recombinase activity in arterial endothelial cells. The Bmx-Cre-ERT2 mouse is an ideal tool in the study of gene function in angiogenesis, atherosclerosis and neovascularisation.
Model Type: Deleter
Genetic Background: C57BL/6 or FVB/N
Zygosity: Heterozygous
Phenotype Keywords:
Disease Keywords: Angiogenesis
Production Details:

A Bmx-Cre-ERT2 transgene vector, containing a genomic VECad promoter fragment fused to a Cre-ERT2 cDNA, was injected into fertilised embryos (C57BL/6 or FVB/N). Founder lines were back-crossed to establish mice heterozygous for the Bmx-Cre-ERT2 transgene.

References:

None yet.

Notes:

Administration of tamoxifen induces nuclear translocation of the Cre-ERT2 fusion protein, and subsequent Cre recombinase activity, allowing knockout/knockin/transgene studies of loxP flanked genes in endothelial cells.
Non-induced Bmx-Cre-ERT2 mice demonstrate no Cre recombinase activity, while tamoxifen-induced Bmx-Cre-ERT2 mice demonstrate high penetrance in endothelial cells (95%+), significantly higher than existing endothelial Cre models currently available. The Bmx-Cre-ERT2 mouse is an ideal tool in the study of gene function in angiogenesis, atherosclerosis and neovascularisation.